News and Media

Product Launch Announcement: Sorafemax 200 (Sorafenib 200mg) Tablet We are proud to introduce Sorafemax 200 is a prescription oral anticancer medication containing Sorafenib 200mg, a well-established multikinase inhibitor used in the management of specific advanced cancers. Designed to inhibit tumor cell proliferation and angiogenesis, Sorafemax 200 (Sorafenib 200mg) plays a critical role in targeted cancer therapy….

🚀Product Launch Announcement: Enzamale 40 (Enzalutamide 40mg) Capsules We are proud to introduce Enzamale 40 (Enzalutamide 40 mg) capsule is an advanced androgen-receptor inhibitor formulated to support the treatment of metastatic and non-metastatic castration-resistant prostate cancer (mCRPC & nmCRPC). Designed with high-purity API and optimized bioavailability, Enzamale delivers consistent therapeutic performance by blocking key androgen-receptor signaling…

🚀Product Launch: Abiramale 250 We are proud to introduce Abiramale 250 contains Abiraterone Acetate 250 mg, an advanced androgen-biosynthesis inhibitor designed to improve outcomes in metastatic castration-resistant prostate cancer (mCRPC).By selectively inhibiting the CYP17 enzyme, Abiramale 250 reduces androgen production from the testes, adrenal glands, and tumor tissue—helping slow disease progression and enhance patient survival. Designed…

🚀 Product Launch Content: Molnuheal 200 We are proud to introduce Molnuheal 200, an oral antiviral formulation containing Molnupiravir 200 mg, designed to address the urgent need for early outpatient treatment of mild to moderate COVID-19 infection in adults at high risk of disease progression. Molnuheal 200 represents a critical step in outpatient COVID-19 management—helping…

🚀 Product Launch Content: Starquin 200 We are pleased to introduce Starquin 200, a clinically trusted formulation of Hydroxychloroquine Sulphate 200 mg, developed to meet the evolving needs in the management of rheumatoid arthritis and systemic lupus erythematosus (SLE). As a cornerstone in autoimmune disease therapy, Starquin 200 delivers consistent efficacy, excellent tolerability, and long-term…

🚀 Product Launch Content: Parziworm 600 We are proud to introduce Parziworm 600, an advanced, high-strength antiparasitic formulation featuring Praziquantel 600 mg, specially designed for the treatment of tapeworm infections, Schistosomiasis, and liver fluke infestations. Backed by robust clinical evidence and global therapeutic relevance, Parziworm 600 stands as a trusted choice for healthcare professionals seeking…

🚀 Product Launch Content: Wormisect 444 We are proud to introduce Wormisect 444, our high-dose, next-generation solution in the fight against parasitic infections. Formulated with Fenbendazole 444 mg, this advanced oral anthelmintic is specifically designed for patients who require enhanced dosing in the management of intestinal helminths. Wormisect 444 is positioned to meet the evolving…

🚀 Product Launch: Wormisect 222 We are pleased to announce the launch of Wormisect 222, our latest pharmaceutical innovation in parasitic infection management. Formulated with Fenbendazole 222 mg, this advanced anthelmintic therapy is engineered for enhanced efficacy against a broad range of gastrointestinal worms, offering both therapeutic and preventive benefits. 🔬 Product Overview Fenbendazole is…

Product Launch: Wormisect 150 We are proud to launch Wormisect 150, a trusted anthelmintic solution formulated with Fenbendazole 150 mg, aimed at providing broad-spectrum treatment for intestinal worm infections. Designed for clinical reliability and patient safety, Wormisect 150 ensures effective parasite clearance with a proven safety profile. 🔬 About Wormisect 150 ⚙️ Mechanism of Action…